US 11,986,481 B2
Method of synthesizing thyroid hormone analogs and polymorphs thereof
Martha J. Kelly, Collegeville, PA (US); Rebecca Taub, Villanova, PA (US); and Edward Hung Yang Chiang, Yardley, PA (US)
Assigned to Madrigal Pharmaceuticals, Inc., West Conshohocken, PA (US); and Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Madrigal Pharmaceuticals, Inc., West Conshohocken, PA (US); and Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Dec. 22, 2023, as Appl. No. 18/393,813.
Application 15/046,213 is a division of application No. 14/660,720, filed on Mar. 17, 2015, granted, now 9,266,861, issued on Feb. 23, 2016.
Application 18/393,813 is a continuation of application No. 18/066,677, filed on Dec. 15, 2022.
Application 18/066,677 is a continuation of application No. 17/118,706, filed on Dec. 11, 2020, granted, now 11,564,926, issued on Jan. 31, 2023.
Application 17/118,706 is a continuation of application No. 16/458,546, filed on Jul. 1, 2019, granted, now 10,894,050, issued on Jan. 19, 2021.
Application 16/458,546 is a continuation of application No. 15/949,389, filed on Apr. 10, 2018, granted, now 10,376,517, issued on Aug. 13, 2019.
Application 15/949,389 is a continuation of application No. 15/046,213, filed on Feb. 17, 2016, granted, now 9,968,612, issued on May 15, 2018.
Application 14/660,720 is a continuation of application No. PCT/US2013/060177, filed on Sep. 17, 2013.
Claims priority of provisional application 61/790,432, filed on Mar. 15, 2013.
Claims priority of provisional application 61/702,137, filed on Sep. 17, 2012.
Prior Publication US 2024/0122936 A1, Apr. 18, 2024
Int. Cl. A61K 31/53 (2006.01); A61K 31/50 (2006.01); A61P 5/14 (2006.01); A61P 9/00 (2006.01); C07D 237/16 (2006.01); C07D 403/02 (2006.01); C07D 403/12 (2006.01)
CPC A61K 31/53 (2013.01) [A61K 31/50 (2013.01); A61P 5/14 (2018.01); A61P 9/00 (2018.01); C07D 237/16 (2013.01); C07D 403/02 (2013.01); C07D 403/12 (2013.01); C07B 2200/13 (2013.01); Y02P 20/55 (2015.11)] 18 Claims
 
1. A method for treating a fatty liver disease in a subject, comprising:
administering to the subject 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile or a pharmaceutically acceptable salt thereof at a dosage of from about 20 mg to about 100 mg per day.